• 首页期刊简介编委会刊物订阅专栏专刊电子刊学术动态联系我们English
引用本文:戴东波,徐金中,尤文挺,胡利明,陈才铭,尚小广.盐酸阿霉素聚乳酸纳米粒的制备及大鼠体内药动学研究[J].中国现代应用药学,2017,34(8):1127-1132.
DAI Dongbo,XU Jinzhong,YOU Wenting,HU Liming,CHEN Caiming,SHANG Xiaoguang.Preparation of Doxorubicin-loaded PLA Nanoparticles and Study Their Pharmacokinetics in Rats[J].Chin J Mod Appl Pharm(中国现代应用药学),2017,34(8):1127-1132.
【打印本页】   【HTML】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2132次   下载 1709 本文二维码信息
码上扫一扫!
分享到: 微信 更多
盐酸阿霉素聚乳酸纳米粒的制备及大鼠体内药动学研究
戴东波1, 徐金中1, 尤文挺1, 胡利明1, 陈才铭1, 尚小广2
1.温岭市第一人民医院药剂科, 浙江 温岭 317500;2.杭州医学院药学系, 杭州 310053
摘要:
目的 优化盐酸阿霉素聚乳酸纳米粒(DOX-PLA-NPs)的制备工艺,并对其理化性质、体外释放及大鼠体内药动学进行研究。方法 采用改良的复乳-溶剂挥发法制备DOX-PLA-NPs,正交设计优化其处方工艺,对其纳米粒形态、粒径、Zeta电位、包封率与载药量进行测定。以DOX原药为对照组,考察DOX-PLA-NPs的体外释药特性及大鼠尾静脉给药后的体内药动学参数。结果 DOX-PLA-NPs外观圆整,平均粒径为(125.67±3.80) nm、Zeta电位为(-35.97±1.58) mV、包封率和载药量分别为(81.23±1.46)%,(10.29±0.63)%。体外释放结果显示,DOX经纳米粒包裹后,具明显的缓释作用。DOX原药和纳米粒的体内药动学过程均符合开放式二室模型,t1/2β分别为(1.15±0.175) h、(6.43±2.12) h,CL分别为(174.76±47.22) h·L-1、(30.68±11.86) h·L-1,AUC0→t分别为(6.01±1.61)μg·h·L-1、(36.04±13.72)μg·h·L-1结论 制备的盐酸阿霉素聚乳酸纳米粒粒径较小、包封率较高,具明显的缓释作用,并能提高药物的生物利用度。
关键词:  盐酸阿霉素  聚乳酸纳米粒  体外释放  药动学
DOI:10.13748/j.cnki.issn1007-7693.2017.08.012
分类号:R944
基金项目:温岭市科技计划项目(2016C311090)
Preparation of Doxorubicin-loaded PLA Nanoparticles and Study Their Pharmacokinetics in Rats
DAI Dongbo1, XU Jinzhong1, YOU Wenting1, HU Liming1, CHEN Caiming1, SHANG Xiaoguang2
1.Department of Pharmacy, The First People's Hospital of Wenling, Wenling 317500, China;2.Department of Pharmaceutical Science, Hangzhou Medical College, Hangzhou 310053, China
Abstract:
OBJECTIVE To optimize the preparation of doxorubicin-loaded PLA nanoparticles (DOX-PLA-NPs), and evaluate their physicochemical properties, release behavior in vitro and study their pharmacokinetics in rats. METHODS The DOX-PLA-NPs were prepared by modified double emulsification(W/O/W) solvent evaporation method. Orthogonal test was used to optimize the preparation procedure. The morphology, size distribution, Zeta potential, encapsulation efficiency, and drug loading of DOX-PLA-NPs were characterized. The drug release behavior in vitro and pharmacokinetics behavior in vivo was investigated in comparison with DOX-sol. RESULTS The optimized nanoparticles were spherical in shape with the mean particle size of (125.67±3.80)nm and the Zeta potential of (-35.97±1.58)mV. The encapsulation efficiency and drug loading were (81.23±1.46)%, (10.29±0.63)%, respectively. In vitro drug release results showed DOX-PLA-NPs had a sustained release character. In in vivo study, the pharmacokinetic behavior of DOX-sol and DOX-PLA-NPs were best fitted to two-compartment model and the parameters were as follows:t1/2β (1.15±0.175)h, (6.43±2.12)h, CL(174.76±47.22) h·L-1, (30.68±11.86)h·L-1, AUC0→t(6.01±1.61)μg·h·L-1, (36.04±13.72)μg·h·L-1. CONCLUSION The optimized DOX-PLA-NPs is practicable with small particle size, high encapsulation efficiency, a certain sustained release characteristic and can significantly improve the bioavailability after vein injection.
Key words:  doxorubicin  PLA nanoparticles  in vitro release  pharmacokinetics
扫一扫关注本刊微信